Post by Windward Bio

We’re excited to announce the successful close of a $165M crossover financing led by OrbiMed, with participation from existing Series A investors and new investors RA Capital Management, Janus Henderson Investors, Sanofi Ventures, and Harbour BioMed. This financing enables continued progress across our programs as we work to bring new treatment options to people living with serious immunological diseases. Read more: https://lnkd.in/etjE8tbw